Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 1
2020 5
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.
Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G. Drilon A, et al. Among authors: delasos l. Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2. Cancer Discov. 2018. PMID: 29610121 Free PMC article. Clinical Trial.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: delasos l. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896
Primary Bone Lymphoma: A Case Series and Review of Literature.
Bindal P, Desai A, Delasos L, Mulay S, Vredenburgh J. Bindal P, et al. Among authors: delasos l. Case Rep Hematol. 2020 Apr 10;2020:4254803. doi: 10.1155/2020/4254803. eCollection 2020. Case Rep Hematol. 2020. PMID: 32328322 Free PMC article.
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. Hayashi T, et al. Among authors: delasos l. Dis Model Mech. 2020 Dec 14;14(2):dmm047779. doi: 10.1242/dmm.047779. Online ahead of print. Dis Model Mech. 2020. PMID: 33318047 Free PMC article.
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG. Drilon A, et al. Among authors: delasos l. Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7. Ann Oncol. 2016. PMID: 27056998 Free PMC article.
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R. Odintsov I, et al. Among authors: delasos l. J Thorac Oncol. 2021 Jul;16(7):1149-1165. doi: 10.1016/j.jtho.2021.03.013. Epub 2021 Apr 8. J Thorac Oncol. 2021. PMID: 33839363
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R. Odintsov I, et al. Among authors: delasos l. Clin Cancer Res. 2021 Jun 1;27(11):3154-3166. doi: 10.1158/1078-0432.CCR-20-3605. Epub 2021 Apr 6. Clin Cancer Res. 2021. PMID: 33824166 Free article.